The United States has imposed sanctions on two Indian nationals and an India-based online pharmacy for their alleged role in supplying counterfeit fentanyl-laced pills to American consumers, intensifying global scrutiny on illicit online pharmaceutical trade and its role in fueling the opioid crisis.
According to a statement from the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC), the individuals – Sadiq Abbas Habib Sayyed and Khizar Mohammad Iqbal Shaikh – were identified as participants in the large-scale distribution of counterfeit prescription medications containing fentanyl and other synthetic opioids. The designated India-based online pharmacy was accused of facilitating the distribution, selling pills that mimicked legitimate prescription drugs but were instead laced with illicit substances.
The move underscores the growing international dimensions of the fentanyl epidemic in the United States. Synthetic opioids, particularly fentanyl, have become the leading driver of overdose deaths, contributing to what U.S. authorities have described as the most severe drug crisis in the country’s history. Fentanyl overdose is currently the leading cause of death among Americans aged 18 to 45.
John K. Hurley, Under Secretary for Terrorism and Financial Intelligence, said the action reflected Washington’s commitment to curbing the spread of fentanyl. “Too many families have been torn apart by fentanyl. Today, we are acting to hold accountable those who profit from this poison. Treasury will continue to advance the commitment to make America fentanyl-free by targeting drug traffickers,” Hurley noted in the statement.
The sanctions are issued under the broader U.S.-India Drug Policy Framework, which aims to foster collaboration between the two countries in combating drug trafficking, enhancing public health measures, and securing global pharmaceutical supply chains. While the framework has strengthened bilateral cooperation on regulatory standards and surveillance, incidents such as this highlight vulnerabilities in online drug distribution channels.
OFAC’s statement pointed out that illegal online pharmacies, some operating from India, have become critical enablers of the crisis. These entities often market themselves as legitimate suppliers of brand-name or generic drugs but deliver counterfeit products instead. Such pills frequently resemble authentic medications, misleading consumers into believing they are purchasing safe treatments. In many cases, however, the products contain fentanyl or other illicit synthetic opioids, exposing users to high risks of overdose.
The agency also flagged the role of precursor chemicals supplied by online operators, which are sometimes diverted to criminal networks abroad. Mexican cartels, in particular, have been reported to source precursor chemicals from suppliers in Asia, including India, to manufacture fentanyl in clandestine laboratories before trafficking it into the United States.
For India, the sanctions signal a need for tighter oversight of online pharmaceutical operations and digital pharmacies. While India is a global leader in the manufacture and export of legitimate generic medicines, cases of illicit trade threaten the sector’s reputation and raise questions around regulatory enforcement.
The development also reinforces the importance of joint monitoring under the U.S.-India Drug Policy Framework. As synthetic opioids continue to dominate global drug enforcement agendas, both countries face the challenge of balancing a robust generic export ecosystem with stronger measures to detect, regulate, and eliminate illicit online suppliers.
